Danavorexton
http://dbpedia.org/resource/Danavorexton an entity of type: Thing
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist known as TAK-994, the development of which was discontinued for safety reasons in October 2021.
rdf:langString
rdf:langString
Danavorexton
xsd:integer
67027040
xsd:integer
1084888141
xsd:integer
21
xsd:integer
2114324
xsd:integer
4650341
xsd:integer
68011464
xsd:integer
32
rdf:langString
methyl -3--2-[oxymethyl]piperidine-1-carboxylate
xsd:integer
2
xsd:integer
5
xsd:integer
130310079
xsd:integer
1
rdf:langString
COCN1CCC[C@@H]NSC
xsd:integer
1
rdf:langString
UXZAJSZFFARTEI-GUMHCPJTSA-N
rdf:langString
TAK-925
xsd:integer
1
xsd:integer
225
rdf:langString
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist known as TAK-994, the development of which was discontinued for safety reasons in October 2021.
xsd:nonNegativeInteger
4864
xsd:string
2114324-48-8
xsd:string
4650341
xsd:string
1QMD83K4YN
xsd:string
130310079